eMAPS 3
Market Access for Partners
Challenge
eMAPS 3 targeted entrepreneurs, innovators, SMEs and others in the life science sector. Gave entrepreneurs and SMEs access to practical knowledge that can be applied to gain market access, allowing them to bring products to market in a sustainable and cost-effective way. Through this platform aimed to accelerate innovation adoption to improve the health of European citizens. eMAPS 3 covers the area of the drugs and biotech products; medical devices and diagnostics; and digital health solutions.
Solution
The eMAPs platform is an innovative learning portal to support entrepreneurs and innovators to navigate the complex processes and pathways involved in accessing healthcare markets (drugs and biotech products; medical devices and diagnostics; and digital health solutions) across Europe. The eMAPS 3 proposal further developed the platform by adding much needed information on Germany, Italy and Portugal as well as the US.
Objectives, Activities and Results expected / achieved
The expected outcome of the eMAPs 3 project is an increase in the number of entrepreneurs and SMEs with the necessary skills and knowledge to be able to navigate the complex systems and processes involved in market access and innovation adoption in other 4 healthcare markets.
Upskilling Innovators : the eMAPs team expect learners to come from mixed posions regarding their base knowledge. After compleng assigned modules, components and chapters, learners will be expected to reach an agreed competency level. We would expect that the programme changes learners’ ways of thinking about bringing an innovation to market. Through having knowledge of the challenges of all the barriers ahead, innovators can plan with the end in mind, allowing them to build more resilient market access plans giving them a higher chance of success.
The result achieved was the creation of a module on the Emaps platform about the Portuguese market, namely regarding drugs and biotechnology products, medical devices and diagnostics, and digital health solutions.
Project Reference
19113Funding
Intervention Region
EuropeTotal Investment
614.339,00IPN Investment
35.000,00Total Eligible
614.339,00IPN Eligible
35.000,00EC Funding – Total
614.339.00EC Funding – IPN
35.000,00Duration
12 MonthsStart Date
2019-01-01End Date
2019-12-31Approval Date
2019-03-11Consortium
Achmea Zorgverzekeringen NV.Friedrich-Alexander-Universität Erlangen-Nürnberg
Universitätsklinikum Erlangen
Instituto Pedro Nunes
Oxford University Hospitals NHS Foundation Trust
Universitá degli Studi Di Napoli Federico II
Website
https://clinicalinnovation.org.uk/project/emaps-knowledge-hub-industry-clinical-innovators/Keywords
Drugs and biotech products;Medical devices and diagnostics;
Digital health solutions.
